Literature DB >> 10022739

Biological role of HGF/MET pathway in renal cell carcinoma.

S Horie1, S Aruga, H Kawamata, N Okui, T Kakizoe, T Kitamura.   

Abstract

PURPOSE: Several lines of evidence show that hepatocyte growth factor (HGF) and its receptor MET play a significant role in the progression of various cancers including renal cell carcinoma (RCC). Our objectives were to evaluate the gene expression of HGF and MET in RCC, and to examine the effect of HGF on the biological activities of cultured RCC cells.
MATERIALS AND METHODS: We examined the gene expression of HGF and MET in 27 primary RCC tumors by quantitative competitive RT-PCR. The effects of HGF on in vitro chemoinvasion assay and the expression of matrix metalloproteinase-9 (MMP-9), and the induction of Fas-induced apoptosis were studied by transfection of HGF cDNA to cultured RCC cells, Caki-1.
RESULTS: HGF mRNA and MET mRNA were detected in all surgical specimens. The level of expressed HGF mRNA was proportional with the volume of tumor (r = 0.50, p = 0.015). Caki-1 cells overexpressing HGF cells showed enhanced in vitro invasiveness in the chemoinvasion assay and increased activity of 92 kDa type IV collagenase (MMP-9). The sensitivity to Fas-induced cell death was reduced in HGF transfectants, which was reversed by the presence of anti-HGF antibody.
CONCLUSIONS: HGF enhanced the invasive properties of cultured RCC cells and inhibited Fas-induced apoptosis in vitro. Both HGF and MET mRNA were expressed in RCC tissues tested. Our results indicate that HGF/MET pathway may have a significant role in the progression of RCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022739

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma.

Authors:  Jiwei Huang; BaiJun Dong; Jin Zhang; Wen Kong; Yonghui Chen; Wei Xue; Dongming Liu; Yiran Huang
Journal:  Tumour Biol       Date:  2014-03-09

3.  Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

Authors:  Mingchao Wang; Yin Sun; Junjie Xu; Jieyang Lu; Kefeng Wang; Dong-Rong Yang; Guosheng Yang; Gonghui Li; Chawnshang Chang
Journal:  Int J Cancer       Date:  2018-04-02       Impact factor: 7.396

4.  MET expression in sporadic renal cell carcinomas.

Authors:  Jong Sun Choi; Mi-Kyung Kim; Jin Won Seo; Yoon-La Choi; Dong Hoon Kim; Yi Kyeong Chun; Young Hyeh Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Critical role of TRPC6 channels in the development of human renal cell carcinoma.

Authors:  Jiayin Song; Yong Wang; Xue Li; Yanna Shen; Meilin Yin; Yuhong Guo; Lei Diao; Yunde Liu; Dan Yue
Journal:  Mol Biol Rep       Date:  2013-05-23       Impact factor: 2.316

6.  Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.

Authors:  L Zhou; X-D Liu; M Sun; X Zhang; P German; S Bai; Z Ding; N Tannir; C G Wood; S F Matin; J A Karam; P Tamboli; K Sircar; P Rao; E B Rankin; D A Laird; A G Hoang; C L Walker; A J Giaccia; E Jonasch
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

7.  A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

Authors:  Hyung L Kim; Susan Halabi; Ping Li; Greg Mayhew; Jeff Simko; Andrew B Nixon; Eric J Small; Brian Rini; Michael J Morris; Mary-Ellen Taplin; Daniel George
Journal:  EBioMedicine       Date:  2015-09-08       Impact factor: 8.143

8.  Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Authors:  Antonietta Rosella Farina; Andrew Reay Mackay
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.